Phase 2b Clinical Trial to Evaluate the Tolerability and Efficacy in Reducing the Nasal Viral Load of SARS-CoV-2 of Benzalkonium Chloride 0.0065% (GX-03), in the Form of Nasal Ointment, in Patients Infected With COVID -19, and Evaluation of Its Tolerability in Health Care Providers, as a Preventive of Nasal Colonization, Complementary to Personal Protective Equipment
Latest Information Update: 12 Jul 2021
At a glance
- Drugs Benzalkonium chloride (Primary) ; Petrolatum
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Turn Therapeutics
Most Recent Events
- 12 Jul 2021 New trial record